Schonfeld Strategic Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.7K	Buy	+11,300	New	+$28.8K	﹤0.01%	2032
2025 Q3	–	Sell	-15,929	Closed	-$18.5K	–	2154
2025 Q2	$18.5K	Buy	+15,929	New	+$17.1K	﹤0.01%	1937
2024 Q3	–	Sell	-73,619	Closed	-$178K	–	1990
2024 Q2	$178K	Sell	73,619 -384,865	-84%	-$1.23M	﹤0.01%	1825
2024 Q1	$1.86M	Sell	458,484 -103,058	-18%	-$388K	0.01%	1018
2023 Q4	$2.16M	Sell	561,542 -83,570	-13%	-$248K	0.01%	774
2023 Q3	$2.68M	Buy	+645,112	New	+$3.99M	0.02%	731
2022 Q4	–	Sell	-152,429	Closed	-$1.53M	–	2539
2022 Q3	$1.53M	Buy	152,429 +36,400	+31%	+$209K	0.01%	1005
2022 Q2	$545K	Buy	116,029 +29,486	+34%	+$111K	0.01%	1320
2022 Q1	$338K	Hold	86,543	–	–	﹤0.01%	1613
2021 Q4	$585K	Buy	+86,543	New	+$951K	0.01%	1183

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Schonfeld Strategic Advisors's ABOS Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 11,300 shares worth $26.7K. The stake represents ﹤0.01% of the portfolio and ranks #2032 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ABOS as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in ABOS in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.68M in Q3 2023. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Schonfeld Strategic Advisors held 11,300 shares of Acumen Pharmaceuticals worth $26.7K as of Q1 2026.
Acumen Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #2032 holding.
Schonfeld Strategic Advisors first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Schonfeld Strategic Advisors's Acumen Pharmaceuticals position peaked at $2.68M in Q3 2023.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.